Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients
AssigneeCellectis
InventorsPhilippe Duchateau, Jean-Pierre Cabaniols, Julien Valton, Laurent Poirot
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for developing engineered immune cells such as T-cells for immunotherapy that have a higher potential of persistence and/or engraftment in host organism. IN particular, this method involves an inactivation of at least one gene involved in self/non self recognition, combined with a step of contact with at least one non-endogenous immunosuppressive polypeptide. The invention allows the possibility for a standard and affordable adoptive immunotherapy, whereby the risk of GvH is reduced.
Claims22
An isolated engineered primary T cell not having the PD-1 gene inactivated, wherein the T cell contains an exogenous nucleic acid molecule expressing PD-L1 under a membrane-bound form that has at least 85% amino acid identity with SEQ ID NO:
- 18 and an exogenous nucleic acid molecule expressing a CTLA-4 immunoglobulin that has at least 85% amino acid identity with SEQ ID NO:
- 16 or SEQ ID NO:
- 17.
An isolated engineered primary T cell not having the PD-1 gene inactivated, wherein the isolated engineered primary T cell contains an exogenous nucleic acid molecule expressing PD-L1 under a membrane-bound form that has at least 95% amino acid identity with SEQ ID NO:
- 18, and wherein the isolated engineered primary T cell expresses a Chimeric Antigen Receptor (CAR).
Dependencies are inferred from the claim text.